NCT06837129

Intravenous Nalbuphine for Prevention of Intrathecal Morphine-induced Nausea and Vomiting in Patients Undergoing Cesarean Section: A Double-blind, Randomized Controlled Trial.

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 180 (actual)
• Sponsor: Thammasat University · Academic / Other
• Sex: Female
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

We study efficacy of iv nalbuphine in prevention of intrathecal morphine-induced nausea and vomiting in patients undergoing cesarean section.

Detailed description

IV nalbuphine has been proved to help prevent intrathecal morphine-induced pruritus in some studies but results in nausea vomiting prevention have not been well studied. In Thailand, most caesarean section is done under spinal anesthesia with intrathecal morphine, proving that iv nalbuphine is effective would be beneficial for our population. This study aims to see whether 4 mg of nalbuphine is effective in reducing incidence of intrathecal morphine-related nausea vomiting in parturient who underwent C-section under spinal anesthesia with 0.2 mg of intrathecal morphine.

Conditions

• Intrathecal Morphine
• Caesarean Section
• Postoperative Nausea and Vomiting
• Neuraxial Opioid

Interventions

Type	Name	Description
DRUG	A single dose of 4 mg iv nalbuphine	prevention of nausea vomiting

Timeline

• Start date: 2023-11-15
• Primary completion: 2025-02-15
• Completion: 2025-02-20
• First posted: 2025-02-20
• Last updated: 2026-01-28

Locations

2 sites across 1 country: Thailand